Methods and compositions comprising DNA damaging agents and p53

Details Methods and compositions comprising DNA damaging agents and p53 Methods and compositions comprising DNA damaging agents and p53

2006-09-19

2006-09-19

Ketter, James (Department: 1636)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100, C536S023100, C536S024100

Reexamination Certificate

active

07109179

ABSTRACT:
The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.

REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4980289 (1990-12-01), Temin et al.
patent: 5055400 (1991-10-01), Lo et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5366737 (1994-11-01), Eppstein et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5496731 (1996-03-01), Xu et al.
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6090566 (2000-07-01), Vogelstein et al.
patent: 6410010 (2002-06-01), Zhang et al.
patent: 6797702 (2004-09-01), Roth et al.
patent: 0174608 (1985-09-01), None
patent: 0351585 (1989-06-01), None
patent: 0390323 (1990-10-01), None
patent: 0475623 (1991-08-01), None
patent: 0510691 (1992-10-01), None
patent: 2688514 (1993-09-01), None
patent: 04-009338 (1992-01-01), None
patent: 8-508879 (1996-09-01), None
patent: WO 90/05180 (1990-05-01), None
patent: WO 90/10448 (1990-09-01), None
patent: WO 91/15580 (1991-10-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/10814 (1993-06-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 93/22443 (1993-11-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/11301 (1995-04-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14101 (1995-05-01), None
patent: WO 95/14102 (1995-05-01), None
patent: WO 95/23867 (1995-09-01), None
patent: WO 95/30002 (1995-11-01), None
Baker et al., “Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carinomas,”Science, 244:217-221, 1989.
Culver, et al, “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, 256:1550-1552, 1992.
Nguen et al., “Gene therapy for lung cancer: enhancement of tumor suppression by a combinationo f sequential systemic cisplatin and adenovirus-medicated p53 gene transfer,”J. Thoracic and Cardiovascular Surgery, 112(5):1372-1377, 1996.
Parsons et al.,J. Heterocyclic Chem., 25:911-914, 1988.
Rubin,Cancer: Priciples and Practice of Oncology, 4thED. Chapter 16, 276-286, Lippincott-Raven, NY, 1993.
Shimizu et al., “Structure of the Ki-rasGene of the Human Lung Carcinoma Cell Line Calu-1,”Nature, 304:497-500, 1983.
Smith et al., “Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice,”Nature Genetics, 5:397-402, 1993.
Stone et al., “Reversible, p16-mediated cell cycle arrest as protection from chemotherapy,”Cancer Res., 56(14):3199-3202, 1996.
Anderson, “Human Gene Therapy,”Nature, 392:25-30, Apr. 30, 1998.
Bacchetti et al., “Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein,”Int. J. Oncol., 3(5):781-788, 1993.
Baker et al., “Suppression of human colorectal carcinoma cell growth by wild-type p53”,Science, 249:912-915, 1990.
Baker et al., “p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis,”Cancer Research, 50:7717-7722, Dec. 1990.
Bandyopadhyay and Temin, “Expression of complete chicken thymidine kinsase gene inserted in a tetrovirus vector,”Mol. Cell. Biol., 4(4):749-754, 1984.
Bargonetti et al., “Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication,”Cell, 65:1083-1091, 1991.
Berkner, “Development of adenovirus vectors for the expression of heterologous genes”,BioTechniques, 6(7):616-629, 1988.
Blenis, “Signal transductionviathe MAP kinases: Proceed at your own RISK”,Proc. Natl. Acad. Sci. USA, 90:5889-5892, 1993.
Bowtell et al., “Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes,”J. Virol., 62(7):2464-2473, 1988.
Brachman et al., “p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines”,Cancer Res., 53:3667-3669, 1993.
Brown et al., “Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines,”Int. J. Cancer, 55:678-684, 1993.
Brown et al., “Mutant p53 confers cisplatin-sensitivity to resistant ovarian tumour cells with elevated wild-type p53,”Proc. Am. Assoc. Cancer Res., 34:355, Abstract #2116, 1993.
Cai et al., “Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer,”Hum. Gene Ther., 4:617-24, 1993.
Capecchi, “Altering the genome by homologous recombination”,Science, 244:1288-1292, 1989.
Carter et al., “Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency,”Virology, 191:473-476, 1992.
Casey et al., “Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene,”Oncogene, 6:1791-1797, 1991.
Casson et al., “p53 gene mutations in Barrett's epithelium and esophageal cancer,”Cancer Res., 51:4495-4499, 1991.
Chang et al., “Inhibition of intratracheal lung cancer development by systemic delivery of EIA,”Oncogene, 13:1405-1412, 1996.
Chang et al., “Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy,”Arch Otolaryngol Head Neck Surg., 123:507-512, 1997.
Chen et al., “Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate,”Oncogene, 6:1799-1805, 1991.
Chen et al., “Genetic mechanisms of tumor suppression by the human p53 gene,”Science, 250:1576-1580, 1990.
Cheng et al., “Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene,”Cancer Res., 52:222-226, 1992.
Clarke et al., “Thymocyte apoptosis induced by p53-dependent and independent pathways,”Nature, 362:849-852, 1993.
Coleman et al., “Radiation and chemotherapy sensitizers and protectors”,Critical Reviews In Oncology/Hematology, 10(Issue 3):225-252, 1990.
Colicos et al., Construction of a recombinant adenovirus containing thedenVgene from bacteriophase T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts,Carcinogenesis, 12(2):249-255, 1991.
Comings, “A general theory of carcinogenesis,”Proc. Natl. Acad. Sci. USA, 70(12-Part I):3324-3328, 1973.
Conroy, “New gene therapy cleared for use against lung cancer,”Biotech Daily, pp. 3-4, 1992.
Co-pending U.S. Appl. No. 07,665,538, filed Mar. 6, 1991 (UTSC:171).
Co-pending U.S. Appl. No. 08/145,826, filed Oct. 29, 1993 (INRP:005).

Affiliated with

Also associated with

Rating

Methods and compositions comprising DNA damaging agents and p53 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions comprising DNA damaging agents and p53, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions comprising DNA damaging agents and p53 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3533376